^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    NUP98-KDM5A fusion

    i
    Other names: KDM5A, Lysine Demethylase 5A, RBBP2, [Histone H3]-Trimethyl-L-Lysine(4) Demethylase 5A, Jumonji/ARID Domain-Containing Protein 1A, Lysine (K)-Specific Demethylase 5A, Retinoblastoma-Binding Protein 2, Lysine-Specific Demethylase 5A, Histone Demethylase JARID1A, JARID1A, RBBP-2, RBP2, Jumonji, AT Rich Interactive Domain 1A (RBBP2-Like), Jumonji, AT Rich Interactive Domain 1A (RBP2-Like), Jumonji, AT Rich Interactive Domain 1A, Retinoblastoma Binding Protein 2, NUP98, Nucleoporin 98 And 96 Precursor 2, Nuclear Pore Complex Protein Nup98-Nup96 2, Nucleoporin 98kDa, Nucleoporin 96, Nup98-Nup96, Nup98-96, NUP96, Nuclear Pore Complex Protein Nup98, GLFG-Repeat Containing Nucleoporin, NUP98/PHF23 Fusion 2 Protein, Nucleoporin 98kD, Nucleoporin 98, NUP196, ADIR2, ADAR2
    Entrez ID:
    4928; 5927
    Related biomarkers:
    Mutation
    Fusion
    Others
    almost3years
    Frequent Detection of CBFA2T3/GLIS2 Fusion and RAM Phenotype with Possible Novel Relationship between RAM Phenotype and Aberrant Cytoplasmic CD3 Expression in Pediatric Non-Down Syndrome Acute Megakaryoblastic Leukemia (USCAP 2022)
    The dismal outcomes in pediatric non-DS-AMKL require more effective therapeutic interventions. The identification of CBFA2T3/GLIS2 fusions and/or RAM-immunophenotype is highly desirable as anti-CD56 may serve as a potential therapeutic intervention. The possible relationship between aberrant cCD3 and RAM immunophenotype in non-DS-AMKL is a novel finding.
    Clinical • IO biomarker
    |
    KMT2A (Lysine Methyltransferase 2A) • CD38 (CD38 Molecule) • NUP98 (Nucleoporin 98 And 96 Precursor 2) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • NCAM1 (Neural cell adhesion molecule 1) • CBFA2T3 (CBFA2/RUNX1 Partner Transcriptional Co-Repressor 3) • GLIS2 (GLIS Family Zinc Finger 2) • KDM5A (Lysine Demethylase 5A) • MLLT10 (MLLT10 Histone Lysine Methyltransferase DOT1L Cofactor)
    |
    KMT2A rearrangement • MLL rearrangement • CBFA2T3 - GLIS2 fusion • NUP98-KDM5A fusion
    almost3years
    Frequent Detection of CBFA2T3/GLIS2 Fusion and RAM Phenotype with Possible Novel Relationship between RAM Phenotype and Aberrant Cytoplasmic CD3 Expression in Pediatric Non-Down Syndrome Acute Megakaryoblastic Leukemia (USCAP 2022)
    The dismal outcomes in pediatric non-DS-AMKL require more effective therapeutic interventions. The identification of CBFA2T3/GLIS2 fusions and/or RAM-immunophenotype is highly desirable as anti-CD56 may serve as a potential therapeutic intervention. The possible relationship between aberrant cCD3 and RAM immunophenotype in non-DS-AMKL is a novel finding.
    Clinical • IO biomarker
    |
    KMT2A (Lysine Methyltransferase 2A) • CD38 (CD38 Molecule) • NUP98 (Nucleoporin 98 And 96 Precursor 2) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • NCAM1 (Neural cell adhesion molecule 1) • CBFA2T3 (CBFA2/RUNX1 Partner Transcriptional Co-Repressor 3) • GLIS2 (GLIS Family Zinc Finger 2) • KDM5A (Lysine Demethylase 5A) • MLLT10 (MLLT10 Histone Lysine Methyltransferase DOT1L Cofactor)
    |
    KMT2A rearrangement • MLL rearrangement • CBFA2T3 - GLIS2 fusion • NUP98-KDM5A fusion